Epileptic Encephalopathy – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Epileptic Encephalopathy – Drugs In Development, 2024 report and make more profitable business decisions.
Epileptic encephalopathies, characterized by epileptiform abnormalities and progressive cerebral dysfunction, present in eight age-related syndromes as per the International League Against Epilepsy. Neonatal syndromes include early myoclonic encephalopathy and Ohtahara syndrome, while infancy sees West syndrome and Dravet syndrome. Childhood and adolescence encompass myoclonic status, Lennox-Gastaut syndrome, Landau-Kleffner syndrome, and epilepsy with continuous spike waves during slow wave sleep. Diagnosis entails EEG examination in both sleep and wake states, along with brain MRI to identify structural defects. Metabolic profiling checks for inherited metabolic issues. STXBP1 mutation testing is advised for Ohtahara syndrome. Treatment focuses on suppressing epileptiform discharges; drugs like valproate, benzodiazepines, levetiracetam, ethosuximide, and sulthiame have proven most effective.
The Epileptic Encephalopathy drugs in development market research report provide comprehensive information on the therapeutics under development for Epileptic Encephalopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epileptic Encephalopathy and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Epileptic Encephalopathy | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 19 molecules, with 19 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Epileptic Encephalopathy therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Epileptic Encephalopathy pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Epileptic Encephalopathy treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Biohaven LtdBiom Therapeutics LLC
CuroNZ Ltd
EpyGenix Therapeutics Inc
GenEp Inc
Jazz Pharmaceuticals Plc
Longboard Pharmaceuticals Inc
Mahzi Therapeutics Inc
Neurocrine Biosciences Inc
Praxis Precision Medicines Inc
Quiver Bioscience Inc
Saniona AB
Supernus Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
Zynerba Pharmaceuticals Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Epileptic Encephalopathy reports